Moreover, the 36-month beta value for ABIO is 0.90. Analysts have varying opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ABIO is 14.31M and currently, short sellers hold a 1.37% of that float. On April 19, 2024, ABIO’s average trading volume was 1.40M shares.
ABIO) stock’s latest price update
The stock of ARCA biopharma Inc (NASDAQ: ABIO) has increased by 4.31 when compared to last closing price of 3.25. Despite this, the company has experienced a 4.95% gain in its stock price over the last five trading sessions. InvestorPlace reported 2024-04-03 that Clinical-stage biopharmaceutical firm ARCA Biopharma (NASDAQ: ABIO ) — which develops and commercializes cardiovascular disease therapies — saw its shares skyrocket during the midweek session. Earlier this morning, management announced a merger with Oruka Therapeutics, which ultimately aims to address chronic skin diseases.
ABIO’s Market Performance
ARCA biopharma Inc (ABIO) has experienced a 4.95% rise in stock performance for the past week, with a 93.71% rise in the past month, and a 110.56% rise in the past quarter. The volatility ratio for the week is 5.35%, and the volatility levels for the past 30 days are at 6.34% for ABIO. The simple moving average for the last 20 days is 30.28% for ABIO stock, with a simple moving average of 75.18% for the last 200 days.
Analysts’ Opinion of ABIO
Many brokerage firms have already submitted their reports for ABIO stocks, with Ascendiant Capital Markets repeating the rating for ABIO by listing it as a “Buy.” The predicted price for ABIO in the upcoming period, according to Ascendiant Capital Markets is $2 based on the research report published on February 27, 2018 of the previous year 2018.
Dawson James, on the other hand, stated in their research note that they expect to see ABIO reach a price target of $3.75. The rating they have provided for ABIO stocks is “Buy” according to the report published on October 09th, 2013.
ABIO Trading at 66.34% from the 50-Day Moving Average
After a stumble in the market that brought ABIO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -12.63% of loss for the given period.
Volatility was left at 6.34%, however, over the last 30 days, the volatility rate increased by 5.35%, as shares surge +90.73% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +112.19% upper at present.
During the last 5 trading sessions, ABIO rose by +5.11%, which changed the moving average for the period of 200-days by +67.24% in comparison to the 20-day moving average, which settled at $2.68. In addition, ARCA biopharma Inc saw 99.41% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for ABIO
The total capital return value is set at -0.2. Equity return is now at value -13.57, with -13.19 for asset returns.
Based on ARCA biopharma Inc (ABIO), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -17.91. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is 16.21.
Currently, EBITDA for the company is -7.3 million with net debt to EBITDA at 5.14. The liquidity ratio also appears to be rather interesting for investors as it stands at 59.01.
Conclusion
To wrap up, the performance of ARCA biopharma Inc (ABIO) has been better in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
